The Phase III KEYNOTE-361 trial evaluating Keytruda (pembrolizumab), in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (bladder cancer) did not meet its pre-specified dual primary endpoints of overall survival (OS) or progression-free survival (PFS), compared with standard of care chemotherapy.
Keytruda, which is US pharma giant Merck & Co’s (NYSE) best-selling drug with 2019 sales of $11.08 billion, is already approved for a number of cancer indications, including as monotherapy for certain people with non-muscle invasive bladder cancer (NMIBC).
Following release of the KEYNOTE-361 results yesterday, Merck’s shares closed down 0.77% at $82.26.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze